Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Apellis Pharmaceuticals Inc shares valued at $58,086 were purchased by Nicholson Nur on Jan 13 ’26. At $22.19 per share, Nicholson Nur acquired 2,618 shares.
Also, Chopas James George purchased 873 shares, netting a total of over 19,369 in proceeds.
Before that, Watson David O. had added 5,780 shares to its account. In a trade valued at $128,242, the Officer bought Apellis Pharmaceuticals Inc shares for $22.19 each.
As published in their initiating research note from Wolfe Research on November 06, 2025, Apellis Pharmaceuticals Inc [APLS] has been a Peer perform. Analysts at Wells Fargo started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid October. As of September 26, 2025, Goldman has decreased its “Neutral” rating to a “Sell” for APLS. Earlier on May 09, 2025, Raymond James downgraded its rating. Their new recommendation was “an Outperform” for APLS stock which previously was a “a Strong buy”.
Analyzing APLS Stock Performance
On last trading session, Apellis Pharmaceuticals Inc [NASDAQ: APLS] plunged -4.69% to $20.33. The stock’s lowest price that day was $20.03, but it reached a high of $21.291 in the same session. During the last five days, there has been a drop of approximately -23.25%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -28.89%.
Is Apellis Pharmaceuticals Inc subject to short interest?
Stocks of Apellis Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 23412.0 shares to 16.12 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 16.1 million shares. A jump of 0.15% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.18 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.18.
Which companies own the most shares of Apellis Pharmaceuticals Inc (APLS)?
In terms of Apellis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 33.5 in the next 12 months, up nearly 57.06% from the previous closing price of $21.33. Analysts anticipate Apellis Pharmaceuticals Inc stock to reach 52 by 2026, with the lowest price target being 19. In spite of this, 14 analysts ranked Apellis Pharmaceuticals Inc stock as Buy at the end of 2026. On May 09, 2025, BofA Securities assigned a price target of “a Neutral” to the stock and downgraded coverage with a $23.
